<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CA56942E-18DE-45C1-8F45-6C572E0F1D0A"><gtr:id>CA56942E-18DE-45C1-8F45-6C572E0F1D0A</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Barrie</gtr:otherNames><gtr:surname>La Thangue</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9400953"><gtr:id>8148E03C-B621-4222-9437-865D33BA034A</gtr:id><gtr:title>Molecular and functional characterisation of the E2F pathway of growth control</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9400953</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1996-06-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4140010</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Structural elucidation of epigenetic regulators</gtr:description><gtr:id>E8BF871B-D7D9-4BC1-A01D-EB01D566E5D2</gtr:id><gtr:impact>Publication of the following papers:
Carr SM, Munro S, Zalmas LP, Fedorov O, Johansson C, Krojer T, Sagum CA, Bedford MT, Oppermann U, La Thangue NB. (2014) Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. Proc Natl Acad Sci U S A. Jul 21. pii: 201403737. [Epub ahead of print]

Munro, S., Oppermann, U. and La Thangue, N.B. (2013) Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer. Oncogene, doi: 10.1038/onc.2013.316. Oncogene 33 (27); 3594-603

Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB (2011) Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO Journal 30: 317-327</gtr:impact><gtr:partnerContribution>Structural biology</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteomics</gtr:description><gtr:id>075FF2BD-252E-43AE-9E88-D505A8CBB0A3</gtr:id><gtr:impact>Publication of the following papers:
Maniam, S., Coutts, A.S., Stratford, M.R., McGouran, J., Kessler, B., and La Thangue, N.B. (2014) p53 regulates oxidative phosphorylation through ATP synthase, Cell Death and Differentiation: in press
Jansson, M., Durant, S.T., Cho, E.C., Sheahan, S., Edelmann, M., Kessler, B., and La Thangue, N.B. (2008). Arginine methylation regulates the p53 response. Nature Cell Biology 10, 1431-1439.</gtr:impact><gtr:partnerContribution>Mass spectrometry</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical Pathology</gtr:description><gtr:id>45E54ABA-B5C2-4181-8271-C3A4FCBD196C</gtr:id><gtr:impact>Publication of the following article:

Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards R. and La Thangue, N. B. (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15 57-66.</gtr:impact><gtr:partnerContribution>Pathology expertise</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminar</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9E9A9A56-DBD7-4386-878C-8971B7A67714</gtr:id><gtr:impact>Seminar to public

wider understanding</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Journal</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>81FFC2AF-790F-4BDC-BEA6-BAC8F94C6EEA</gtr:id><gtr:impact>contribute to journal

distribution to public</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9636F163-76F7-4849-A5A0-E20A6C838D98</gtr:id><gtr:impact>Open days, seminars to the lay public, general reviews in lay journals

More awareness</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The E2F pathway of growth control</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BDFC7DC7-80B0-4F5A-8EF3-FBEACB9AE1FE</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Researchers became specalized in Cancer Research and non-researchers became aware of developments in Cancer Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DAC0CB33-CAC9-4D2B-814B-886377958A5B</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>database of newly identified E2F target genes</gtr:description><gtr:id>1891F356-A4AD-4EFB-9424-15D15F7B78A3</gtr:id><gtr:impact>Freely distributed upon request once published</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Target genes</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Celleron Therapeutics</gtr:companyName><gtr:description>Therapeutic Company; http://cellerontherapeutics.com/</gtr:description><gtr:id>A39A5BEF-C004-444B-A6B6-82F6590CFD40</gtr:id><gtr:impact>Drug discovery</gtr:impact><gtr:url>http://cellerontherapeutics.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Oxford Cancer Biomarkers</gtr:companyName><gtr:description>http://oxfordcancerbiomarkers.com/index2.php</gtr:description><gtr:id>0497172F-395C-4FA5-9C92-216824BB0ED3</gtr:id><gtr:impact>0</gtr:impact><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Profilix</gtr:companyName><gtr:description>Therapeutic; merged with TopoTarget in 2002</gtr:description><gtr:id>0D76D990-1383-45F4-91B2-49CD335F2E2D</gtr:id><gtr:impact>Drug development</gtr:impact></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FA5BA9B-53EC-401E-84DA-50A7422F9FA7"><gtr:id>2FA5BA9B-53EC-401E-84DA-50A7422F9FA7</gtr:id><gtr:title>Targets for cancer chemotherapy: Transcription factors and other nuclear proteins.</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c846b4e500221d1664456dbb785341ac"><gtr:id>c846b4e500221d1664456dbb785341ac</gtr:id><gtr:otherNames> La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:isbn>978-1-59259-153-4</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24CDD707-36A8-41FE-ABF4-160683B27219"><gtr:id>24CDD707-36A8-41FE-ABF4-160683B27219</gtr:id><gtr:title>ATM and Chk2 kinase target the p53 cofactor Strap.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad778125cc3dc9a3b6408f2e444e67f9"><gtr:id>ad778125cc3dc9a3b6408f2e444e67f9</gtr:id><gtr:otherNames>Adams CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C25A9BF-0E13-4C98-8209-3248D4AE1F8E"><gtr:id>4C25A9BF-0E13-4C98-8209-3248D4AE1F8E</gtr:id><gtr:title>CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F243266C-889C-42C5-A12B-22DF711DF18A"><gtr:id>F243266C-889C-42C5-A12B-22DF711DF18A</gtr:id><gtr:title>Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1a.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88F5B507-3408-4BBD-89C8-5325D65AC27E"><gtr:id>88F5B507-3408-4BBD-89C8-5325D65AC27E</gtr:id><gtr:title>TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81AD86DB-C359-4169-99CE-2B9A1EC9E53E"><gtr:id>81AD86DB-C359-4169-99CE-2B9A1EC9E53E</gtr:id><gtr:title>E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad82c3493d178b8d60a78ebe938a1a84"><gtr:id>ad82c3493d178b8d60a78ebe938a1a84</gtr:id><gtr:otherNames>Logan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D27C159-F3D1-4090-95FB-89EE144FDC52"><gtr:id>0D27C159-F3D1-4090-95FB-89EE144FDC52</gtr:id><gtr:title>eLS</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2164989D-07EC-4D27-A98D-87224431C66A"><gtr:id>2164989D-07EC-4D27-A98D-87224431C66A</gtr:id><gtr:title>The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f919f1db2101172fa9e08201e5f439a"><gtr:id>3f919f1db2101172fa9e08201e5f439a</gtr:id><gtr:otherNames>McLaughlin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5730833B-D713-4925-BBE3-8D738D06243C"><gtr:id>5730833B-D713-4925-BBE3-8D738D06243C</gtr:id><gtr:title>Signalling DNA damage by regulating p53 co-factor activity.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d800fe2353c2fd435d4e9f68af2a0c5d"><gtr:id>d800fe2353c2fd435d4e9f68af2a0c5d</gtr:id><gtr:otherNames>Smith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E09B4A26-CEF8-4958-B8F5-4F83A65000CE"><gtr:id>E09B4A26-CEF8-4958-B8F5-4F83A65000CE</gtr:id><gtr:title>Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82278c5ffc8814c46f6eded780bf38c1"><gtr:id>82278c5ffc8814c46f6eded780bf38c1</gtr:id><gtr:otherNames>Chan HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F26E0E0-6956-40AD-AB62-D0637907AFCD"><gtr:id>6F26E0E0-6956-40AD-AB62-D0637907AFCD</gtr:id><gtr:title>E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad82c3493d178b8d60a78ebe938a1a84"><gtr:id>ad82c3493d178b8d60a78ebe938a1a84</gtr:id><gtr:otherNames>Logan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90CB7C66-C90C-4FB9-9D9E-1AE75AA46F92"><gtr:id>90CB7C66-C90C-4FB9-9D9E-1AE75AA46F92</gtr:id><gtr:title>Lysine methylation regulates the pRb tumour suppressor protein.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE52A434-9A8A-4B2A-B26F-04E7418EB36B"><gtr:id>DE52A434-9A8A-4B2A-B26F-04E7418EB36B</gtr:id><gtr:title>HDAC Inhibitors.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/682B9D72-F9A4-416B-AD3A-2094169C8835"><gtr:id>682B9D72-F9A4-416B-AD3A-2094169C8835</gtr:id><gtr:title>Arginine methylation controls growth regulation by E2F-1.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8b164c6197f3a8bf63bf411eda6e674"><gtr:id>a8b164c6197f3a8bf63bf411eda6e674</gtr:id><gtr:otherNames>Cho EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E3EB671-F40B-4ED2-B112-4912B9B38048"><gtr:id>3E3EB671-F40B-4ED2-B112-4912B9B38048</gtr:id><gtr:title>A TPR motif cofactor contributes to p300 activity in the p53 response.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f92b914a585b5b3ecb2c27bd7289197f"><gtr:id>f92b914a585b5b3ecb2c27bd7289197f</gtr:id><gtr:otherNames>Demonacos C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9257E008-869A-4DFA-9F3E-BC3AEE484631"><gtr:id>9257E008-869A-4DFA-9F3E-BC3AEE484631</gtr:id><gtr:title>Arginine methylation regulates the p53 response.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ff45642f7a5434862a9ea70b08268fd"><gtr:id>6ff45642f7a5434862a9ea70b08268fd</gtr:id><gtr:otherNames>Jansson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03672A34-F476-423A-A3DA-E79520C421E6"><gtr:id>03672A34-F476-423A-A3DA-E79520C421E6</gtr:id><gtr:title>Clinical Exemplification of HDAC Inhibitors: From Bench to Clinic, and Back Again</gtr:title><gtr:parentPublicationTitle>The Journal of OncoPathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66369F06-653A-498E-8AE4-1F0D41C6504A"><gtr:id>66369F06-653A-498E-8AE4-1F0D41C6504A</gtr:id><gtr:title>Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc088ca797e035b292f2f3103320da6b"><gtr:id>cc088ca797e035b292f2f3103320da6b</gtr:id><gtr:otherNames>Khan O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1743-4254</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F751523D-947C-4069-97E2-20C369158E69"><gtr:id>F751523D-947C-4069-97E2-20C369158E69</gtr:id><gtr:title>A functionally distinct member of the DP family of E2F subunits.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c70ed01dc2e197ce4f897f4f96f5f2dc"><gtr:id>c70ed01dc2e197ce4f897f4f96f5f2dc</gtr:id><gtr:otherNames>Milton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C14C4D3F-C4D5-4EA2-BDAD-45CC2E7308DC"><gtr:id>C14C4D3F-C4D5-4EA2-BDAD-45CC2E7308DC</gtr:id><gtr:title>The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad778125cc3dc9a3b6408f2e444e67f9"><gtr:id>ad778125cc3dc9a3b6408f2e444e67f9</gtr:id><gtr:otherNames>Adams CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C58B8634-77BD-4166-A627-91B20EB18D60"><gtr:id>C58B8634-77BD-4166-A627-91B20EB18D60</gtr:id><gtr:title>Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 activity through ATP synthase.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b58dcf49b89d2c6b1a1ed379a31a048b"><gtr:id>b58dcf49b89d2c6b1a1ed379a31a048b</gtr:id><gtr:otherNames>Maniam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB9D3292-6B92-46BE-89A9-C9E83A001B4C"><gtr:id>EB9D3292-6B92-46BE-89A9-C9E83A001B4C</gtr:id><gtr:title>Selective inhibition of BET bromodomains.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82d26cad18a3b34bdf077e0d3b841513"><gtr:id>82d26cad18a3b34bdf077e0d3b841513</gtr:id><gtr:otherNames>Filippakopoulos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B739E848-4876-475A-BE54-0F4E3E4963E7"><gtr:id>B739E848-4876-475A-BE54-0F4E3E4963E7</gtr:id><gtr:title>Acetylation control of the retinoblastoma tumour-suppressor protein.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82278c5ffc8814c46f6eded780bf38c1"><gtr:id>82278c5ffc8814c46f6eded780bf38c1</gtr:id><gtr:otherNames>Chan HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0773785C-A9E0-4FE0-A319-25927E3AF231"><gtr:id>0773785C-A9E0-4FE0-A319-25927E3AF231</gtr:id><gtr:title>E2F proteins.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36ff37990f9b56387aab348f9b8b286b"><gtr:id>36ff37990f9b56387aab348f9b8b286b</gtr:id><gtr:otherNames>Loughran O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89C7C0D0-223B-4CF6-BAD5-FEC370A84BF0"><gtr:id>89C7C0D0-223B-4CF6-BAD5-FEC370A84BF0</gtr:id><gtr:title>Signal transduction blockade and cancer: combination therapy or multi-targeted inhibitors?</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68b35d962789b70193cb6eb55f982427"><gtr:id>68b35d962789b70193cb6eb55f982427</gtr:id><gtr:otherNames>Kerr DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD54D88F-8AE7-440F-81B6-B7E3A0FD5BB7"><gtr:id>DD54D88F-8AE7-440F-81B6-B7E3A0FD5BB7</gtr:id><gtr:title>p14(ARF) regulates E2F activity.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf5db26994ddbbd045c104682549488c"><gtr:id>cf5db26994ddbbd045c104682549488c</gtr:id><gtr:otherNames>Mason SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFA31181-FB23-4B49-8DE2-A733EB41D747"><gtr:id>AFA31181-FB23-4B49-8DE2-A733EB41D747</gtr:id><gtr:title>Apoptotic and growth-promoting activity of E2F modulated by MDM2.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36ff37990f9b56387aab348f9b8b286b"><gtr:id>36ff37990f9b56387aab348f9b8b286b</gtr:id><gtr:otherNames>Loughran O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08E7014A-E926-4030-AE0E-4E52AD9B3575"><gtr:id>08E7014A-E926-4030-AE0E-4E52AD9B3575</gtr:id><gtr:title>HDAC inhibitor-based therapies: can we interpret the code?</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24722F06-3802-447C-8479-53B138A33465"><gtr:id>24722F06-3802-447C-8479-53B138A33465</gtr:id><gtr:title>Oncology biomarkers in clinical practice - a new horizon</gtr:title><gtr:parentPublicationTitle>Drug Target Review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c95c284bc6b418511194748af9d10d95"><gtr:id>c95c284bc6b418511194748af9d10d95</gtr:id><gtr:otherNames>Sheikh, S.,</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B3087848-49EA-495F-9A5F-7EB016A743F9"><gtr:id>B3087848-49EA-495F-9A5F-7EB016A743F9</gtr:id><gtr:title>Chk2 activates E2F-1 in response to DNA damage.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e44fcfb9fb3237b0ce7a55d7295b2a46"><gtr:id>e44fcfb9fb3237b0ce7a55d7295b2a46</gtr:id><gtr:otherNames>Stevens C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10DA0C7A-6F44-4C5A-A5EE-8B08B7B756FC"><gtr:id>10DA0C7A-6F44-4C5A-A5EE-8B08B7B756FC</gtr:id><gtr:title>A transcription co-factor integrates cell adhesion and motility with the p53 response.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85EE5227-83AB-4EE2-A357-6FCA9DCB854E"><gtr:id>85EE5227-83AB-4EE2-A357-6FCA9DCB854E</gtr:id><gtr:title>Mdm2 targets the p53 transcription cofactor JMY for degradation.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F036873-5841-482A-A3BF-9311E7D8DCA8"><gtr:id>7F036873-5841-482A-A3BF-9311E7D8DCA8</gtr:id><gtr:title>Post-translational control of transcription factors: methylation ranks highly.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2EF6405E-1C31-4728-8819-70DF408A0702"><gtr:id>2EF6405E-1C31-4728-8819-70DF408A0702</gtr:id><gtr:title>To live or let die - complexity within the E2F1 pathway.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e4b1d53b64045b4809079e1aabcead13"><gtr:id>e4b1d53b64045b4809079e1aabcead13</gtr:id><gtr:otherNames>Poppy Roworth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2372-3556</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19A92AA6-5402-4F66-9556-7DB046FAE330"><gtr:id>19A92AA6-5402-4F66-9556-7DB046FAE330</gtr:id><gtr:title>The emerging role of E2F-1 in the DNA damage response and checkpoint control.</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e44fcfb9fb3237b0ce7a55d7295b2a46"><gtr:id>e44fcfb9fb3237b0ce7a55d7295b2a46</gtr:id><gtr:otherNames>Stevens C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50B4372B-93A0-45AB-BC06-A5BF74603004"><gtr:id>50B4372B-93A0-45AB-BC06-A5BF74603004</gtr:id><gtr:title>A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58E21465-EA26-48A6-8534-4AB61B20351E"><gtr:id>58E21465-EA26-48A6-8534-4AB61B20351E</gtr:id><gtr:title>Histone deacetylase inhibitors and cancer therapy.</gtr:title><gtr:parentPublicationTitle>Journal of chemotherapy (Florence, Italy)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1120-009X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/262954B2-43E4-4CA7-8384-027632C474B9"><gtr:id>262954B2-43E4-4CA7-8384-027632C474B9</gtr:id><gtr:title>Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response.</gtr:title><gtr:parentPublicationTitle>Science advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/645d826a2aac8cfef39f45eabd8af26e"><gtr:id>645d826a2aac8cfef39f45eabd8af26e</gtr:id><gtr:otherNames>Ghari F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2375-2548</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A60ED88C-2563-4DAE-A11E-BE3100CE0D67"><gtr:id>A60ED88C-2563-4DAE-A11E-BE3100CE0D67</gtr:id><gtr:title>Histone deacetylase inhibitors open new doors in cancer therapy.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f919f1db2101172fa9e08201e5f439a"><gtr:id>3f919f1db2101172fa9e08201e5f439a</gtr:id><gtr:otherNames>McLaughlin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F13B6A3F-A536-43E6-881E-3151BE44363B"><gtr:id>F13B6A3F-A536-43E6-881E-3151BE44363B</gtr:id><gtr:title>E2F-7 couples DNA damage-dependent transcription with the DNA repair process.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c28a22b36d3a50c513cbeeb2da12fd5"><gtr:id>9c28a22b36d3a50c513cbeeb2da12fd5</gtr:id><gtr:otherNames>Zalmas LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D17ABF7-87B6-4E8E-8283-5F0B31AF588C"><gtr:id>0D17ABF7-87B6-4E8E-8283-5F0B31AF588C</gtr:id><gtr:title>Actin nucleators in the nucleus: an emerging theme.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8680c526c850249788ecad73d36a8e3b"><gtr:id>8680c526c850249788ecad73d36a8e3b</gtr:id><gtr:otherNames>Weston L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9087E9B-87E6-4959-90DC-297A8186832A"><gtr:id>F9087E9B-87E6-4959-90DC-297A8186832A</gtr:id><gtr:title>Atypical E2F activity restrains APC/CCCS52A2 function obligatory for endocycle onset.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19d155d0032e1658191904ad1cf0d763"><gtr:id>19d155d0032e1658191904ad1cf0d763</gtr:id><gtr:otherNames>Lammens T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B51FF451-E9E6-4856-8E05-5F92D8A61CAB"><gtr:id>B51FF451-E9E6-4856-8E05-5F92D8A61CAB</gtr:id><gtr:title>SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E33718D-8B45-4704-B552-609509139B0D"><gtr:id>7E33718D-8B45-4704-B552-609509139B0D</gtr:id><gtr:title>A transcription cofactor required for the heat-shock response.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e8d926f151e1a5ca9c91291369227789"><gtr:id>e8d926f151e1a5ca9c91291369227789</gtr:id><gtr:otherNames>Xu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF7A0361-F151-4067-8E1A-0F6A10260DEC"><gtr:id>BF7A0361-F151-4067-8E1A-0F6A10260DEC</gtr:id><gtr:title>Histone deacetylase inhibitors: gathering pace.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/742a6355de110b9584a2adba20e667a8"><gtr:id>742a6355de110b9584a2adba20e667a8</gtr:id><gtr:otherNames>Carey N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/162590A5-FCE9-488F-B971-1A34DB850DA3"><gtr:id>162590A5-FCE9-488F-B971-1A34DB850DA3</gtr:id><gtr:title>The yin and yang of E2F-1: balancing life and death.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54BFA225-CCC2-4B3B-AC95-F88B4561DBB8"><gtr:id>54BFA225-CCC2-4B3B-AC95-F88B4561DBB8</gtr:id><gtr:title>Transcription. Chromatin control--a place for E2F and Myc to meet.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CD368A1-B108-4C02-9550-70112F2DD521"><gtr:id>0CD368A1-B108-4C02-9550-70112F2DD521</gtr:id><gtr:title>A new effector pathway links ATM kinase with the DNA damage response.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f92b914a585b5b3ecb2c27bd7289197f"><gtr:id>f92b914a585b5b3ecb2c27bd7289197f</gtr:id><gtr:otherNames>Demonacos C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43B44420-EEAE-4170-B811-3824FF27199F"><gtr:id>43B44420-EEAE-4170-B811-3824FF27199F</gtr:id><gtr:title>Actin nucleation by a transcription co-factor that links cytoskeletal events with the p53 response.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B964B61B-9E03-4195-843E-BB3EC273211C"><gtr:id>B964B61B-9E03-4195-843E-BB3EC273211C</gtr:id><gtr:title>Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88d2cb4b08cd1931093e1e6e19a74d41"><gtr:id>88d2cb4b08cd1931093e1e6e19a74d41</gtr:id><gtr:otherNames>Kawalkowska J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BD39F5F-5566-44C2-8828-2783702BE64D"><gtr:id>5BD39F5F-5566-44C2-8828-2783702BE64D</gtr:id><gtr:title>The p53 response: emerging levels of co-factor complexity.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E6C29ED-1E8E-4A13-8398-84502F795756"><gtr:id>5E6C29ED-1E8E-4A13-8398-84502F795756</gtr:id><gtr:title>Structural analysis of human KDM5B guides histone demethylase inhibitor development.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7bee931d752a276728f5b7a8b416a9c9"><gtr:id>7bee931d752a276728f5b7a8b416a9c9</gtr:id><gtr:otherNames>Johansson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8BA8C07A-529F-43BA-8690-CA634D24FA85"><gtr:id>8BA8C07A-529F-43BA-8690-CA634D24FA85</gtr:id><gtr:title>A new role for E2F-1 in checkpoint control.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e44fcfb9fb3237b0ce7a55d7295b2a46"><gtr:id>e44fcfb9fb3237b0ce7a55d7295b2a46</gtr:id><gtr:otherNames>Stevens C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF67BF8E-62C5-4527-8969-0F30F0140335"><gtr:id>DF67BF8E-62C5-4527-8969-0F30F0140335</gtr:id><gtr:title>DNA-damage-responsive acetylation of pRb regulates binding to E2F-1.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e9c0478acc75cd63b43c1995cdddccd"><gtr:id>1e9c0478acc75cd63b43c1995cdddccd</gtr:id><gtr:otherNames>Markham D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8709FEAC-3A7F-4AE7-B7EE-66EF2DC0A2FF"><gtr:id>8709FEAC-3A7F-4AE7-B7EE-66EF2DC0A2FF</gtr:id><gtr:title>14-3-3 proteins integrate E2F activity with the DNA damage response.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e390e2d09ed33768c8a0df64d125ef2a"><gtr:id>e390e2d09ed33768c8a0df64d125ef2a</gtr:id><gtr:otherNames>Milton AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2609D96E-F3A9-4D21-ADEA-BD73BEE1F9B5"><gtr:id>2609D96E-F3A9-4D21-ADEA-BD73BEE1F9B5</gtr:id><gtr:title>Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/220BA1D2-A56C-4465-925A-A3746345F3D1"><gtr:id>220BA1D2-A56C-4465-925A-A3746345F3D1</gtr:id><gtr:title>A mismatched role for Bcl-2.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D7A8CDA-DE38-4DAF-86B7-A86938A4B017"><gtr:id>5D7A8CDA-DE38-4DAF-86B7-A86938A4B017</gtr:id><gtr:title>Drug discovery and the p53 family.</gtr:title><gtr:parentPublicationTitle>Progress in cell cycle research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f92b914a585b5b3ecb2c27bd7289197f"><gtr:id>f92b914a585b5b3ecb2c27bd7289197f</gtr:id><gtr:otherNames>Demonacos C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1087-2957</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5763A107-6B87-4313-86E3-BBAA9315413B"><gtr:id>5763A107-6B87-4313-86E3-BBAA9315413B</gtr:id><gtr:title>Selective inhibition of BET bromodomains.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82d26cad18a3b34bdf077e0d3b841513"><gtr:id>82d26cad18a3b34bdf077e0d3b841513</gtr:id><gtr:otherNames>Filippakopoulos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0EEF5C27-7CED-4614-BECE-6CD7F1DC2976"><gtr:id>0EEF5C27-7CED-4614-BECE-6CD7F1DC2976</gtr:id><gtr:title>Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87f635b36caf42ee4a3707f76a2784ef"><gtr:id>87f635b36caf42ee4a3707f76a2784ef</gtr:id><gtr:otherNames>Plumb JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9400953</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>